NEW YORK, March 1, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced today that Dr. Robert Preti, PhD, President and Chief Scientific Officer of Progenitor Cell Therapy ("PCT"), a wholly-owned subsidiary of NeoStem, Inc., has been asked to present on Tuesday, March 1, 2011 at the 6th Annual New York Stem Cell Summit. The Summit will be held at Bridgewaters New York at 11 Fulton Street, New York, NY. Dr. Preti will present as part of the Adult Stem Cell track at 2:11 pm.
Dr. Preti is co-founder of Progenitor Cell Therapy, LLC, an internationally recognized cell therapy services and development company. Through his administrative duties, Dr. Preti has overseen the growth of PCT from its inception to the world's leading commercial cell therapy company. He is one of the country's leading authorities on cell engineering, advanced cell and gene therapy manufacturing, testing and delivery, and regulatory aspects relating to the cell therapy and regenerative medicine industry and has been a pioneer of cell manufacturing as with Dendreon's product Provenge which just received FDA approval in 2010. He has been the principal investigator for a number of clinical trials relating to the clinical testing of cellular therapies. Previous positions held by Dr. Preti include Scientific and Laboratory Director of Hackensack University Medical Center's stem cell processing and research laboratory and Scientific Director of the Clinical Services Division at the New York Blood Center.
The Company acquired PCT in January 2011. PCT, through its cGMP certified manufacturing facilities and team of professionals, facilitates the preclinical and clinical development and eventual commercialization of cellular therapies for clients in the United States and internationally.
Dr. Robert Preti said, "I am honored to be invited to be one of approximately 35 scheduled leaders of the stem cell industry to speak at this event. Progenitor Cell Therapy is a client-based cell therapy services company that supports the development of cellular therapies. We have extensive experience and expertise in having processed over 30,000 cell therapy product procedures and shipped over 5,000 cell therapy products for transplantation over the last ten years. The full range of our services for cell therapy clients include consulting, product and process development, processing, manufacturing, storage, and transport."
The New York Stem Cell Summit is organized and sponsored by Robin R. Young, CFA, President of RRY Publications, LLC. According to the Summit's website, the Summit "will bring the future of this dynamic industry to life for investors, industry, practitioners, and analysts."
About NeoStem, Inc.
NeoStem, Inc. is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company. NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally. The Company also has licensed various cellular therapy technologies, including worldwide exclusive licenses to a wound healing technology and to VSEL™ Technology which uses very small embryonic-like stem cells, which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells.
For more information, please visit: http://www.neostem.com.
About the New York Stem Cell Summit
The WSAF has been the leading independent sponsor of over 80 analyst conferences in NYC, Boston & London since 1989. Over 2,500 corporations have participated ranging from Motorola, Inc., Mattel, Inc., General Electric, to Pfizer, Inc. Institutional investors from over 2000 money management firms have attended. Our conferences receive coverage in The WSJ, Barron's, CNBC, and Bloomberg.
For more information, please visit: http://www.analyst-conference.com/.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the ability of PCT's business to complement NeoStem's adult stem cell operations and successful execution of the Company's strategy, as well as other advances in the Company's business, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, its Form S-4/A filed with the Securities and Exchange Commission on December 3, 2010 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. NeoStem may experience difficulties in integrating PCT's business and could fail to realize potential benefits of the merger. Acquisitions may entail numerous risks for NeoStem, including difficulties in assimilating acquired operations, technologies or products, including the loss of key employees from acquired businesses.
SOURCE NeoStem, Inc.